Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study-Reference-Cited by-同舟云学术

Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study

Published:2021-08 Issue:8 Volume:43 Page:1285-1299
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Ghosh Nilanjan,Emond Bruno,Lafeuille Marie-Hélène,Côté-Sergent Aurélie,Lefebvre Patrick,Huang Qing

Funder

AbbVie

Janssen Pharmaceuticals Inc

Gilead Sciences

Janssen Scientific Affairs

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. Gene mutations and actionable genetic lesions in mantle cell lymphoma;Ahmed;Oncotarget,2016

2. Leukemia & Lymphoma Society. Mantle cell lymphoma facts. https://www.lls.org/sites/default/files/file_assets/mantlecelllymphoma.pdf. 2021

3. National Cancer Institute. SEER cancer stat facts: non-Hodgkin lymphoma. 2020; https://seer.cancer.gov/statfacts/html/nhl.html. Accessed January 7, 2021.

4. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management;Vose;Am J Hematol,2015

5. Systematic literature review of the global burden of illness of mantle cell lymphoma;Monga;Curr Med Res Opin,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs;Leukemia & Lymphoma;2023-07-27

3. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database;Advances in Therapy;2022-08-19

4. Ibrutinib ± rituximab for MCL saves costs versus chemoimmunotherapy;PharmacoEconomics & Outcomes News;2021-08

5. On Target: Extending Lifespans, Improving QALYs, and Reducing Costs with Adjunct Monoclonal Antibody Therapies for Cancer;Clinical Therapeutics;2021-08